Sign In

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.


Evolva starts Phase I Clinical Trials on EV-077

Basel, Switzerland, 18 March 2009 - Evolva SA, an international biotech company focused on the discovery and development of drugs based on its genetic chemistry platform, today announced it has started Phase I Clinical Trials with its drug candidate EV-077-3201-2TBS.

The first-in-man study, a single ascending dose study, will enroll 56 healthy male volunteers and will be conducted in Germany over the next 12 weeks. The purpose of the study is to assess the safety and tolerability of EV-077-3201-2TBS and evaluate its pharmacokinetic profile and pharmacodynamic effects.

Dr. Alexandra Santana Sorensen, VP R&D of Evolva said: “We are very pleased and excited to have reached a significant Milestone by entering Phase I studies with our first drug candidate. We believe that EV-077-3201-2TBS has a very interesting potential in a number of cardiovascular and renal indications.”

EV-077-3201-2TBS is a new chemical entity, with a different mode of action from existing drugs that are being developed for cardiovascular and renal indications.

About Evolva
Evolva uses its genetic chemistry platform to replicate, on an industrial basis, the ability of nature to create small molecules with exquisite “design”. Based on this technology, the Company has a number of third party discovery and pre-clinical programs. Evolva’s drug development activities focus on cardiovascular, renal and infectious diseases. The Company had revenues of about CHF 10 million in 2008. For more information see

Contact Details
Alexandra Santana Sorensen
Phone: +41 61 485 20 20
Fax: +41 61 485 20 01

Publisher Contact Information:

Evolva SA
+41 61 485 20 20

Company profile of Evolva SA
Past press releases of Evolva SA.


Tech investments
From our Online Data Service
VC-backed companies
From our Radar

Recent Deals

Nov 25€24.0MInternet commerce
Nov 8N/AOther Computers & Electronics
Nov 5€2.1MAudio/Video
Nov 5€5.2MOther Computers & Electronics
Nov 5€0.4MInternet services
Nov 5€1.3MSecurity
Nov 5€1.5MAudio/Video

For information on Europe's most extensive database on technology funding click here!


Press Releases

Sep 30
tetavi raises $6 million to help more companies bring 3d holograms ...

May 28
identiq raises $5m seed, launches privacy-first identity validation...

Apr 29
nethone raised over $1 million from innovation nest

Mar 31
the fit allocates chf 100'000 to comppair technologies

Jan 29
yumpingo raises $10m to transform guest experiences in restaurants

About usContact usLegal Information
Copyright © 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.